Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.2871
Abstract: Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B‐cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively… read more here.
Keywords: response; indolent cell; cell lymphomas; reduction cycles ... See more keywords
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2022.2043512
Abstract: Abstract Bendamustine plus rituximab (BR) and rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) have been shown to be effective in the treatment of indolent B-cell lymphomas (iBCL). The survival outcomes and adverse events of BR… read more here.
Keywords: meta analysis; chop; plus rituximab; indolent cell ... See more keywords
Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119408
Abstract: Introduction. Elderly patients with chronic lymphocytic leukemia (CLL) are often treated with chemoimmunotherapeutic regimens. Because of ineligibility for Fludarabine-based protocol, Bendamustine plus Rituximab (B-R) or Chlorambucil plus Rituximab (Chl-R) are the common preferred schemes, chosen… read more here.
Keywords: response; group; study; chl ... See more keywords
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.00838
Abstract: PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS Patients had confirmed symptomatic WM, either previously untreated… read more here.
Keywords: ibrutinib rituximab; placebo; innovate; plus rituximab ... See more keywords
Bendamustine plus rituximab: is it a BRIGHT idea?
Sign Up to like & getrecommendations! Published in 2019 at "Chinese clinical oncology"
DOI: 10.21037/cco.2019.10.03
Abstract: Flinn et al . have reported the results of the long-term follow-up for the BRIGHT trial, an international study which compared the efficacy and the safety of bendamustine plus rituximab (BR) with either rituximab plus… read more here.
Keywords: rituximab bright; bendamustine plus; bright idea; oncology ... See more keywords
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s309092
Abstract: Background This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL)… read more here.
Keywords: response; plus rituximab; lymphoma; relapsed refractory ... See more keywords
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2020-0794
Abstract: Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem cell transplant, leaving… read more here.
Keywords: transplant; mantle cell; cell; plus rituximab ... See more keywords
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-1015
Abstract: WHAT IS THIS SUMMARY ABOUT? This article provides a short summary of 5-year results from the iNNOVATE trial. The original paper was published in the Journal of Clinical Oncology in October 2021. People with Waldenström's… read more here.
Keywords: oncology; ibrutinib plus; plus rituximab; waldenstr macroglobulinemia ... See more keywords